The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7525-7529

  Wang, E J ^a   Casciano, C N ^a   Clement, R P ^a   Johnson, W W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DAUNORUBICIN; FARNESYL TRANS TRANSFERASE; GLYCOPROTEIN P; LONAFARNIB; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RHODAMINE 123; VERAPAMIL; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG TRANSPORT; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MICROSOME; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CHO CELLS; CRICETINAE; DAUNORUBICIN; DRUG SYNERGISM; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, MDR; HUMANS; HYDROLYSIS; MICE; P-GLYCOPROTEIN; PACLITAXEL; PIPERIDINES; PYRIDINES; RHODAMINE 123; TAMOXIFEN; VINBLASTINE;

EID: 0035887454     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Biochemistry of multidrug resistance mediated by the multidrug transporter
2. Multidrug resistance and the role of P-glycoprotein knockout mice
3. P-glycoprotein: Its role in drug resistance
4. 6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors
5. Immunohistochemical analysis of P-glycoprotein expression in breast cancer: Clinical correlations
6. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport
7. Reconstitution of drug transport by purified P-glycoprotein
8. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein
9. Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport
10. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities
11. Two transport binding sites of P-glycoprotein are unequal yet contingent: Initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependency
12. Extraction of HOECHST 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein
13. Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: Evidence for half-of-the-sites reactivity
14. Clinical reversal of multidrug resistance
15. Multidrug resistance transporters and modulation
16. Modulation of multidrug-resistant multiple myeloma by cyclosporin
17. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo
18. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo
19. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity
20. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
21. RS-33295-198: A novel potent modulator of P-glycoprotein-mediated multidrug resistance
22. Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells
23. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance
24. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073
25. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance
26. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
27. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models
28. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
29. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein
30. A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: Application to lens ATPases
31. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase
32. ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells
33. ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells
34. Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis
35. Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein
36. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal
37. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein
38. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein: The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes
39. Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in human P-glycoprotein: Evidence for ADP release as the rate limiting step in the limiting step in the catalytic cycle and its modulation by substrates
40. A general pattern for substrate recognition by P-glycoprotein